| P50 | author | Gérard Thiéfin | Q50579136 |
| P2093 | author name string | Bernard Bannwarth | |
| P2860 | cites work | Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. | Q34459461 |
| | Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial | Q34720605 |
| | Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. | Q35595971 |
| | The pharmacology and pathophysiology of leukotriene B4 | Q40137650 |
| | Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury | Q40689497 |
| | Chirality and nonsteroidal anti-inflammatory drugs | Q41217588 |
| | Associations between maternal decaffeinated and caffeinated coffee consumption and fetal growth and gestational duration | Q41650152 |
| | Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. | Q42565360 |
| | Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative | Q42930380 |
| | Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole | Q43861367 |
| | Role of leukotriene C4 in mucosal damage caused by necrotizing agents and indomethacin in the rat stomach | Q43974012 |
| | Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis | Q44165133 |
| | Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis | Q44261800 |
| | COX-3: just another COX or the solitary elusive target of paracetamol? | Q44378635 |
| | Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. | Q50892230 |
| | In Vivo Antithrombotic Effects of a Nitric Oxide-Releasing Aspirin Derivative, NCX-4016 | Q60695438 |
| | A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats | Q60695447 |
| | Markedly reduced intestinal toxicity of a diclofenac derivative | Q60695454 |
| | The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal antiinflammatory drugs in mice | Q69460927 |
| | Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage | Q72687835 |
| | Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats | Q74307016 |
| | Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding | Q74339271 |
| | Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users | Q74844224 |
| | Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects | Q78001458 |
| | Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? | Q24536027 |
| | Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans | Q24669542 |
| | Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs | Q24670111 |
| | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 |
| | Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen | Q28164178 |
| | Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial | Q28165580 |
| | Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation | Q28166417 |
| | Nitric oxide-releasing NSAIDs: a review of their current status | Q28190519 |
| | Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents | Q28192894 |
| | Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use | Q28193290 |
| | Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials | Q28193800 |
| | Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases | Q28193996 |
| | Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study | Q28195152 |
| | Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole | Q28196888 |
| | Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat | Q28244187 |
| | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study | Q29620671 |
| | Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs | Q34093824 |
| | Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs | Q34376929 |
| | Gastric surfactant and the hydrophobic mucosal barrier | Q34410436 |
| | Dual acting anti-inflammatory drugs: a reappraisal | Q34458239 |
| P304 | page(s) | C96-102 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | Gastroenterologie Clinique et Biologique | Q15756157 |
| P1476 | title | [Management of the digestive risk in patients treated with NSAIDs. Synthesis and perspectives] | |
| P478 | volume | 28 Spec No 3 | |